COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia

Journal of Neuroscience Research

Volumn 87, Issue 3, 2009, Pages 677-682

  Tukhovskaya, Elena A ^a,d   Yukin, Alexey Yu ^a   Khokhlova, Oksana N ^a   Murashev, Arkady N ^a   Vitek, Michael P ^b,c  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Optimal Screening Vehicles Division   (United States)

^d NONE   (Russian Federation)

Author keywords

Apolipoprotein E; MCAO; Neuroprotection

Indexed keywords

APOLIPOPROTEIN E; COG 1410; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; DRUG RESPONSE; LOCOMOTION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; VESTIBULAR FUNCTION;

ANIMALS; APOLIPOPROTEINS E; BRAIN; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; KETAMINE; MALE; MOTOR ACTIVITY; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 62849084822     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21874     Document Type: Article

References (42)

1. Aono M, Lee Y, Grant ER, Zivin RA, Pearlstein RD, Warner DS, Bennett ER, Laskowitz DT. 2002. Apolipoprotein E protects against NMDA excitotoxicity. Neurobiol Dis 11:214-220.
2. Aono M, Bennett ER, Kim KS, Lynch JR, Myers J, Pearlstein RD, Warner DS, Laskowitz DT. 2003. Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 116:437-445.
3. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L. 1997. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 17:516-529.
4. Belayev L, Alonso OF, Busto R. Zhao W, Ginsberg MD. 1996. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 27:1616-1622.
5. Bonita R. 1992. Epidemiology of stroke. Lancet 339:342-344.
6. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu G-Q, Xu Q, Fish JD, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. 2004. Neuronspecific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24: 2527-2534.
7. Chang S, Ma TR, Miranda RD, Balestra ME, Mahley RW, Huang Y. 2005. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A 102:18694-18699.
8. Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP. 2002. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 23:777-785.
9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
10. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. 1994. Protective effects of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180-184.
11. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349-1356.
12. Ferro MM. 2007. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease. Braz J Med Biol Res 40:89-96.
13. Fujikawa DG. 1995. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 36:1861-195.
14. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. 2001. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein E knockout mice. Exp Neurol.169:13-22.
15. Gundersen HJ, Jensen EB. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263.
16. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y. 2003. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 100:10966-10971.
17. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. 2001. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98:8838-8843.
18. Laskowitz DT, Goel S, Bennett ER, Matthew WD. 1997. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Neuroimmunol 1-2:70-74.
19. Laskowitz DT, Horsburg K, Roses AD. 1998. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 18:465-471.
20. Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, Bennett ER. 2001. Downregulation of microglial activation by apolipo-protein E and apoE-mimetic peptides. Exp Neurol 167:74-85.
21. Laskowitz DT, Fillet H, Yeung N, Toku K, Vitek MP. 2006. Apolipo-protein E-derived peptides reduce CNS inflammation: Implications for therapy of neurological disease. Acta Neurol Scand 114:15-20.
22. Laskowitz DT, McKenna SE, Wang H, Durham L, Yeung N, Christensen D, Vitek MP. 2007. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurofrauma.24:1093-1107.
23. Lebedev SV, Petrov SV, Blinov DV, Lazarenko IP, Chekhonin VP. 2003. Ketamine-induced rotational asymmetry in evaluation of motor disturbances in rats with middle cerebral artery occlusion. Bull Exp Biol Med 135:424-427.
24. Linton M, Gish R, Hubl S, Butler E, Esquivel C, Bry W, Boyles J, Wardell M. 1991. Phehotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 81:270-281.
25. Lomnitski L, Chapman S, Hochman A, Kohen R, Shoharm E, Chen Y, Trembovler V, Michaelson DM. 1999. Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Biochim Biophys Acta 1453:359-368.
26. Lopez-Martin E, Rozas G, Rodriguez J, Guerra MJ, Labandeira-Garcia JL. 1998. The corticostriatal system mediates the paradoxical contraversive rotation but not the striatal hyperexpression of Fos induced by amphetamine early after 6-hydroxydopamine lesion of the nigrostriatal pathway. Exp Brain Res 120:153-163.
27. Lyden PD, Lu M, Levine SR, Brott TG, Broderick J, NINDS rtPA Stroke Study Group. 2001. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke 32:1310-1317.
28. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. 2001. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114:107-113.
29. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, Warner DS, Laskowitz DT. 2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 278:48529-48533.
30. Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, Vitek MP, McJCenna S, Laskowitz DT. 2005. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 192:109-116.
31. Mahley RW. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622-630.
32. McAdoo JD, Warner DS, Goldberg RN, Vitek MP, Pearlstein R, Laskowitz DT. 2005. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 381:305-308.
33. Methia N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DD. 2001. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 7:810-815.
34. Misra UK, Adlakha CL, Gawdi G, McMillian MK, Pizzo SV, Laskowitz DT. 2001. Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. J Leukocyte Biol 70: 677-683.
35. Miyata M, Smith JD. 1996. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta amyloid peptides. Nat Genet 14:55-61.
36. Nathan BP, Bellosta. S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264:850-852.
37. Scandinavian Stroke Study Group. 1985. Multicenter trial of hemodilution in ischemic stroke-background and study protocol. Stroke 16:885-890.
38. Spilker J, Kongable G, Barch C, Braimah J, Brattina P, Daley S, Donnarumma R, Rapp K, Sailor S. 1997. Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-PA Stroke Study Group. J Neurosci Nurs 29:384-392.
39. Strittmatter WJ, Roses AD. 1996. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 19:53-77.
40. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. 1990. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10:290-293.
41. The World Health Riport. 1999. Geneva: World Health Organization. 119 p.
42. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. 2006. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26:4985-4994.